CORTLANDT MANOR, N.Y., Sept. 13, 2011 /PRNewswire/ -- Polymedco, Inc. is pleased to announce its exclusive agreement with Cardinal Health, Inc., for distribution of its market leading automated FIT product, a fecal occult blood analyzer that can help increase patient compliance rates and aid in the early detection of colorectal cancer. The agreement includes distribution of the OC-Auto Micro 80; automated FIT analyzer; and OC-Sensor Diana, a high throughput automated FIT analyzer, to the acute care market.
The Polymedco tests can help increase patient compliance rates, because, unlike Guaiac tests, they require a single stool sample, have no dietary or medicinal restrictions, and have a completely closed sampling device. With this methodology, patient compliance has been shown to as much as triple over prior testing methods.
"We are extremely pleased to be working with a distributor of the magnitude of Cardinal Health," said Drew Cervasio, president of Polymedco. "Polymedco is excited to offer a test with such lifesaving capability and looking forward to delivering this product to as many hospitals as possible and saving as many more lives with the help of the Cardinal Health organization."
Colorectal cancer is the third-leading cause of cancer death in America, causing 50,000 deaths each year. Yet when detected early, colorectal cancer is highly treatable, and patients with precancerous polyps or early stage cancers often do not have to follow-up with repeated surgeries and costly radiation and chemotherapy. Annual screening for colorectal cancer, which is facilitated by the OC-FIT line of products, is to saving lives and containing healthcare costs.
"Cardinal Health is committed to supporting solutions which drive cost-effectiveness and improve quality outcomes," said Chris Kerski, senior vice president and general manager of scientific products at Cardinal Health. "We're pleased with our partnership with Polymedc